Efficacy in patients with <i>EGFR</i> -positive non-small-cell lung cancer treated with dacomitinib who had skin adverse events: <i>post hoc</i> analyses from ARCHER 1050
<b>Aim:</b> We investigated association between skin adverse events (AEs) and efficacy with dacomitinib in patients with <i>EGFR</i>-positive non-small-cell lung cancer (NSCLC).<b>Methods:</b> <i>Post hoc</i> analyses from ARCHER 1050 evaluated efficacy in patients who did and did not experience grade ≥2 skin AEs with dacomitinib. Landmark analyses were performed at 3 and 6 months.<b>Results:</b> In patients who had skin AEs (72.2%) vs. those who did not (27.7%), median progression-free survival was 16.0 vs. 9.2 months, median overall survival (OS) was 37.7 vs. 21.6 months, and objective response rate was 80.2 vs. 61.5%; OS was improved at 3 and 6 months landmark analyses.<b>Conclusion:</b> Presence of grade ≥2 skin AEs was associated with numerically improved efficacy and represents a valuable biomarker of treatment outcome with dacomitinib in patients with advanced NSCLC.<b>Clinical Trial Registration:</b> NCT01774721 (ClinicalTrials.gov).
Authors
- Weiwei Tan (ORCID: https://orcid.org/0000-0001-8915-1152)
- Adam Płużański (ORCID: https://orcid.org/0000-0002-3710-6445)
- Ki Hyeong Lee (ORCID: https://orcid.org/0000-0002-7830-5950)
- R. Linke (ORCID: https://orcid.org/0000-0002-4529-5848)
- Yiyun Tang (ORCID: https://orcid.org/0000-0001-9810-1288)
- Seiji Niho (ORCID: https://orcid.org/0000-0001-9480-5923)
- Rafael Rosell (ORCID: https://orcid.org/0000-0003-0817-3400)
- Ying Cheng (ORCID: https://orcid.org/0000-0001-9908-597X)
- Xingxiang Pu (ORCID: https://orcid.org/0000-0002-2743-7080)
- Tony Mok (ORCID: https://orcid.org/0000-0002-8251-0551)
- Junling Li (ORCID: https://orcid.org/0000-0002-7361-325X)
- Xiangdong Zhou (ORCID: https://orcid.org/0000-0002-5866-8682)
- Lin Wu (ORCID: https://orcid.org/0000-0001-7078-7767)
- Juan Li (ORCID: https://orcid.org/0000-0003-4110-3295)
- Kazuhiko Nakagawa (ORCID: https://orcid.org/0000-0003-1284-9776)
- Jinyao Zhang (ORCID: https://orcid.org/0000-0001-5657-9013)
- Maria Rita Miglorino
- J. Corral
- Bo Zhang (ORCID: https://orcid.org/0000-0002-7167-4083)
- Fang Pan
Institutions
- Central South University (CN)
- Army Medical University (CN)
- Chinese University of Hong Kong (HK)
- Pfizer (United States) (US)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Shanghai Chest Hospital (CN)
- Kindai University Hospital (JP)
- Instituto Oncológico Dr. Rosell (ES)
- Hunan Cancer Hospital (CN)
- Sichuan Cancer Hospital (CN)
- Clinica Universidad de Navarra (ES)
- National Cancer Center Hospital East (JP)
- Pfizer (China) (CN)
- The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
- Carlo Forlanini Hospital (IT)
- Chungbuk National University Hospital (KR)
Publication Details
- Journal
- Future Oncology
- Published
- 2024-10-03
- DOI
- https://doi.org/10.1080/14796694.2024.2404762
- Citations
- 3
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 1.26
Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Taiho Pharmaceutical
- Kissei
- BeiGene
- Sysmex Corporation
- Kyorin Pharmaceutical
- Puma Biotechnology
- Lunit
- Eisai
- Ono Pharmaceutical
- SymBio Pharmaceuticals Limited
- Novartis Pharma
- Pfizer Japan
- Chugai Pharmaceutical
- MSD K.K.
- Eli Lilly Japan
- Sanofi K.K.
- Daiichi Sankyo Europe